Several advancements across pharmaceutical research and development have been announced, spanning from neurodegenerative diseases to oncology and AI-driven drug discovery.
Largest ALS Patient Data Repository Completed
Answer ALS and Cedars-Sinai have announced the completion of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem cell (iPSC) and bio data repository. This repository encompasses biological and clinical data from nearly 1,000 ALS patients, providing an unprecedented resource for researchers studying ALS, also known as Lou Gehrig's disease. Investigators can access patient-specific iPSCs and differentiated motor neurons to analyze ALS disease progression in lab-created cells and correlate these observations with detailed clinical, genetic, and protein profiles unique to each ALS patient.
AI-Driven Drug Discovery for Rare Diseases
Healx announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform. Sanofi will provide data related to a late-stage discontinued asset being considered for out-licensing. Healnet incorporates recent advances in generative AI to find connections between biological and chemical entities that could be turned into new treatments. Healx will also deploy its drug discovery and development expertise to provide Sanofi with an AI-driven therapeutic rationale to support the compound’s future development.
Single-Cell Protein Profiling Solution Launched
Scale Biosciences and Revvity’s business, BioLegend, announced the availability of TotalSeq Phenocyte, a single-cell protein profiling solution. This solution supports customers in identifying and characterizing rare cell subtypes, ultimately powering immunology and oncology research. It combines Scale Biosciences’ Quantum Barcoding technology platform and BioLegend’s TotalSeq antibody conjugates. The combined offering can be used to power biomarker discovery and the identification of rare cells within a heterogeneous population without complex panel design, complicated workflows, or dedicated instrumentation.
BioNTech Acquires Biotheus to Enhance Oncology Strategy
BioNTech has acquired Biotheus, obtaining full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. This transaction is part of BioNTech’s oncology strategy, aimed at enhancing the company’s capabilities to research, develop, and commercialize combination therapies using BNT327/PM8002. The acquisition aims to further strengthen BioNTech's capabilities to develop, manufacture, and commercialize next-generation bispecific antibodies and novel treatment combinations.
